SAN FRANCISCO, May 7, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2020. Cash and investments in marketable securities at March 31, 2020 were approximately $1.5 billion as compa…
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2020.
Here Is What Hedge Funds Bought And Sold In The Q1 Chaos: Full 13F Summary Tyler Durden Sat, 05/16/2020 - 13:00 Amid a selling panic that at times surpassed the liquidation observed during both the financial crisis and the great depression, hedge funds …
NKTR earnings call for the period ending March 31, 2020.
The Covid-19 outbreak has created some headwinds and delays for Nektar's clinical programs, including top-line data from the crucial PIVOT-10 study of bempeg in first-line melanoma. The PIVOT-02 study continues to support the idea of a significant imp…
Celebrations may be in order for Nektar Therapeutics (NASDAQ:NKTR) shareholders, with the analysts delivering a...
Nektar (NKTR) delivered earnings and revenue surprises of 34.57% and 12.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
This single-arm, phase I dose-escalation trial ([NCT02983045][1]) evaluated bempegaldesleukin (NKTR-214/BEMPEG), a CD122-preferential IL2 pathway agonist, plus nivolumab in 38 patients with selected immunotherapy-naïve advanced solid tumors (melanoma, renal…
Adobe and Avantor make the list Continue reading...
Q1 2020 Nektar Therapeutics Earnings Call
It's finally time to write about my favorite pharma stock in the Corona-discount model. Bristol-Myers-Squibb has gone from being a rather insignificant holding to over 1.5% of my portfolio. I show you why i consider the company one of the better pharm…
SAN FRANCISCO, May 7, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2020. Cash and investments in marketable securities at March 31, 2020 were approximately $1.5 billion as compa…
NKTR earnings call for the period ending March 31, 2020.
Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) in combination with nivolumab, in Cancer Discovery, a journal of the American Association …
H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Tuesday, setting a price target of $26, which is approximately 25.18% above the present share price of $20.77.
SAN FRANCISCO, April 28, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2020 on Thursday, May 7, 2020, after the close of U.S.-based financial markets. Howard Robin, President and Chief Execut…
In the span of eight days last month, CytomX Therapeutics Inc. landed a collaboration with Astellas Pharma and captured a $40 million milestone payment from AbbVie Inc. as it preps for a mid-stage cancer clinical trial. “It’s a challenging time for our industry,” said CytomX President and CEO Sean McCarthy.
Adobe and Avantor make the list Continue reading...
Nektar (NKTR) reports encouraging fourth-quarter results. The company continues to progress with its pipeline candidates.
Nektar (NKTR) reports encouraging first-quarter 2020 results. The company continues to progress with its pipeline candidates.
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2020 on Thursday, May 7, 2020, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Oppenheimer analyst Jay Olson maintained a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Sunday, setting a price target of $25, which is approximately 13.53% above the present share price of $22.02.
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN FRANCISCO, April 28, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2020 on Thursday, May 7, 2020, after the close of U.S.-based financial markets. Howard Robin, President and Chief Execut…
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to present at the upcoming Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time.
Q1 2020 Nektar Therapeutics Earnings Call
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Nektar Therapeutics...
It's been a sad week for Nektar Therapeutics (NASDAQ:NKTR), who've watched their investment drop 12% to US$20.81 in...
Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) in combination with nivolumab, in Cancer Discovery, a journal of the American Association for Cancer Research. Previously published Phase 1 data in Cancer Discovery on BEMPEG, a CD122-preferential IL-2 pathway agonist, demonstrated that when administered as a monotherapy, it was well tolerated and showed clinical activity, including tumor shrinkage and durable disease stabilization, in heavily pretreated patients with solid tumor cancers.1 The manuscript published today presents the safety, immune-activation and efficacy results from a Phase 1 dose-escalation study conducted in 38 patients with immunotherapy-naïve, advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC).
SAN FRANCISCO, May 22, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) in combination with nivolumab, in Cancer Disco…
Q4 2019 Nektar Therapeutics Earnings Call